Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Abstract Background HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have dem...

Full description

Bibliographic Details
Main Authors: Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom, James L. Gulley
Format: Article
Language:English
Published: BMJ Publishing Group 2019-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Interleukin-8 (IL-8)
Metastatic cancer
Solid tumor
HuMax-IL8
BMS-986253
Monoclonal antibody
Online Access:http://link.springer.com/article/10.1186/s40425-019-0706-x

Internet

http://link.springer.com/article/10.1186/s40425-019-0706-x

Similar Items